Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumours

Official Title

A Phase 1/2a, Multicentre, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumours

Summary:

To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumour(s) or intravenously and when combined with pembrolizumab in patients with solid tumours (RIVAL-01).

Trial Description

Primary Outcome:

  • Incidence of adverse events when TBio-6517 administered by direct injection into tumour(s) alone at each dose level
  • Incidence of adverse events when TBio-6517 administered by direct injection into tumour(s) when combined with pembrolizumab
  • Maximum tolerated dose (MTD) or Maximum feasible dose (MFD) and determination of the recommended Phase 2 dose (RP2D) of TBio-6517 alone and in combination with pembrolizumab.
  • Percentage of overall response rate (ORR) by RECIST 1.1 at the RP2D
  • Percentage of overall response rate (ORR) by immunotherapy RECIST (iRECIST) at the RP2D
Secondary Outcome:
  • Number and severity of adverse events at the RP2D
  • Median overall survival (OS)
  • Median Duration of Response (DoR)
  • Proportion of patients with a response (ORR)
  • Median Disease Control Rate (DCR)
  • Time to tumour progression (TTP)
  • Median progression free survival

This is a Phase 1/2a dose escalation study with TBio-6517 administered by direct injection into tumour(s) or by intravenous infusion. The Phase 1 portion has 4 arms; the first arm (Arm A) will determine the RP2D of TBio-6517 alone when directly injected into tumour(s), and the second arm (Arm B) will determine the RP2D of TBio-6517 when combined with pembrolizumab. The third and fourth arms will determine the RP2D of TBio-6517 when given intravenously alone and with pembrolizumab, respectively.

In the Phase 2a portion, the clinical benefit of TBio-6517 combined with pembrolizumab will be further explored in patients with Microsatellite Stable Colorectal Cancer (MSS-CRC), Cholangiocarcinoma (CCA), Cutaneous Melanoma, and Cutaneous Squamous Cell Carcinoma of the Skin (cSCC), as assessed by overall response rate (ORR) from central radiology review.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society